4554 Fuji Pharma Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4554

TSE Prime

Fuji Pharma Co.,Ltd.

1,411

JPY

+13

(+0.93%)

Jul 28, 1:16 pm JST

9.55

USD

Jul 28, 12:16 am EDT

Result

PTS

outside of trading hours

1,412.7

Jul 28, 1:01 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep, 2021	33,990	3,349	3,250	2,432	90.5	29	Nov 5, 2021	J-GAAP
Sep, 2022	35,426	3,777	3,725	2,696	111.0	35	Nov 10, 2022	J-GAAP
Sep, 2023	40,889	3,858	4,519	3,435	141.4	37	Nov 9, 2023	J-GAAP
Sep, 2024	46,138	3,880	4,445	6,146	252.9	42.50	Nov 12, 2024	J-GAAP
Sep, 2025 Guidance	53,360	4,850	4,680	3,380	138.4	45.50	Nov 12, 2024	J-GAAP
YoY	+15.7%	+25.0%	+5.3%	-45.0%	-45.3%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Sep, 2020	Nov 8, 2019	33,830	2,571	2,501	1,664	29	J-GAAP
	May 8, 2020	33,830	2,571	2,501	492	29	J-GAAP
	Jul 1, 2020	33,830	2,571	2,501	1,664	29	J-GAAP
Results	Nov 5, 2020	33,793	3,139	2,983	2,085	29	J-GAAP
Sep, 2021	Nov 5, 2020	Available in future release
Results	Nov 5, 2021
Sep, 2022	Nov 5, 2021
	Nov 2, 2022
Results	Nov 10, 2022
Sep, 2023	Nov 10, 2022
Results	Nov 9, 2023
Sep, 2024	Nov 9, 2023
	Nov 27, 2023
	May 9, 2024
Results	Nov 12, 2024
Sep, 2025	Nov 12, 2024	53,360	4,850	4,680	3,380	45.5	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Sep, 2000	5,855	+5.0	Available in future release
Sep, 2001	6,152	+5.1
Sep, 2002	6,853	+11.4
Sep, 2003	8,676	+26.6
Sep, 2004	9,694	+11.7
Sep, 2005	10,128	+4.5
Sep, 2006	11,240	+11.0
Sep, 2007	13,250	+17.9
Sep, 2008	14,937	+12.7
Sep, 2009	17,198	+15.1
Sep, 2010	19,698	+14.5
Sep, 2011	21,623	+9.8
Sep, 2012	21,520	-0.5
Sep, 2013	25,174	+17.0
Sep, 2014	29,215	+16.1
Sep, 2015	31,680	+8.4
Sep, 2016	34,229	+8.0
Sep, 2017	35,387	+3.4
Sep, 2018	37,909	+7.1
Sep, 2019	36,279	-4.3
Sep, 2020	33,793	-6.9
Sep, 2021	33,990	+0.6
Sep, 2022	35,426	+4.2
Sep, 2023	40,889	+15.4
Sep, 2024	46,138	+12.8
Sep, 2025 Guidance	53,360	+15.7	4,850	+25.0	4,680	+5.3	138.4	-45.3

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Sep, 2023	40,889	3,858	9.44	8.92	4.27	0.51	141.4
Sep, 2024	46,138	3,880	8.41	14.17	7.01	0.53	252.9
Sep, 2025 Guidance	53,360	4,850	9.09	7.39	3.65	0.58	138.4

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	46,138	4,391	4,628	6,146	252.9
Fiscal Year	Sep, 2024	Sep, 2018	Sep, 2017	Sep, 2024	Sep, 2024

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2022	17,700	1,065	859	862	35.5	20	Nov 10, 2022	J-GAAP
Apr - Sep, 2023	21,664	2,034	2,063	1,663	68.4	20	Nov 9, 2023	J-GAAP
Apr - Sep, 2024	24,750	2,437	2,280	1,889	77.7	22.50	Nov 12, 2024	J-GAAP
Apr - Sep, 2025 Guidance	29,265	2,545	2,471	2,093	85.7	25.50	May 8, 2025	J-GAAP
YoY	+18.2%	+4.4%	+8.4%	+10.8%	+10.3%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Sep, 2022	3,777	-11,929	-658	-11,271	5,094	3,546	4.69	J-GAAP
Sep, 2023	3,858	-3,323	1,917	-5,240	1,915	2,324	2.72	J-GAAP
Sep, 2024	3,880	2,493	4,151	-1,658	-435	4,585	5.09	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Oct - Mar, 2022	19,225	1,824	2,456	1,772	73.0	54.3	May 11, 2023	J-GAAP
Oct - Mar, 2023	21,388	1,443	2,165	4,257	175.2	48.7	May 9, 2024	J-GAAP
Oct - Mar, 2024	24,095	2,305	2,209	1,287	52.8	47.2	May 8, 2025	J-GAAP
YoY	+12.7%	+59.7%	+2.0%	-69.8%	-69.8%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Apr - Jun, 2023	10,257	579	285	210	8.6	5.6	Aug 8, 2023	J-GAAP
Jul - Sep, 2023	11,407	1,455	1,778	1,453	59.8	12.8	Nov 9, 2023	J-GAAP
Oct - Dec, 2023	10,746	-140	-96	2,739	112.7	-1.3	Feb 8, 2024	J-GAAP
Jan - Mar, 2024	10,642	1,583	2,261	1,518	62.5	14.9	May 9, 2024	J-GAAP
Apr - Jun, 2024	11,767	772	802	653	26.9	6.6	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	12,983	1,665	1,478	1,236	50.9	12.8	Nov 12, 2024	J-GAAP
Oct - Dec, 2024	13,000	1,252	1,376	991	40.8	9.6	Feb 6, 2025	J-GAAP
Jan - Mar, 2025	11,095	1,053	833	296	12.2	9.5	May 8, 2025	J-GAAP
YoY	+4.3%	-33.5%	-63.2%	-80.5%	-80.5%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Apr - Jun, 2020	7,994	-9.6	Available in future release
Jul - Sep, 2020	8,894	-0.7
Oct - Dec, 2020	9,295	+3.6
Jan - Mar, 2021	7,982	+0.6
Apr - Jun, 2021	8,221	+2.8
Jul - Sep, 2021	8,492	-4.5
Oct - Dec, 2021	9,446	+1.6
Jan - Mar, 2022	8,280	+3.7
Apr - Jun, 2022	8,744	+6.4
Jul - Sep, 2022	8,956	+5.5
Oct - Dec, 2022	9,996	+5.8
Jan - Mar, 2023	9,229	+11.5
Apr - Jun, 2023	10,257	+17.3
Jul - Sep, 2023	11,407	+27.4
Oct - Dec, 2023	10,746	+7.5
Jan - Mar, 2024	10,642	+15.3
Apr - Jun, 2024	11,767	+14.7
Jul - Sep, 2024	12,983	+13.8
Oct - Dec, 2024	13,000	+21.0
Jan - Mar, 2025	11,095	+4.3	1,053	-33.5	833	-63.2	12.2	-80.5

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	13,000	1,725	2,261	2,739	112.7
Fiscal Year	Dec, 2024	Dec, 2017	Mar, 2024	Dec, 2023	Dec, 2023

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Sep, 2022	1,473.73	47.4	75,538	35,803	26,546	0.69	Nov 10, 2022	J-GAAP
Sep, 2023	1,694.23	48.3	85,332	41,174	29,082	0.70	Nov 9, 2023	J-GAAP
Sep, 2024	1,873.52	50.6	90,000	45,549	34,256	0.64	Nov 12, 2024	J-GAAP
Oct - Mar, 2024	ー	49.3	92,672	45,720	34,995	0.71	May 8, 2025	J-GAAP

Fuji Pharma Co.,Ltd.(4554) Financial Results